Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 51407-833

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 51407-833). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51407-832-05lb (Lurasidone HCl)

51407-832-05lb (Lurasidone HCl)
Label for Lurasidone Hydrochloride film-coated tablets, 40 mg strength. The label shows NDC 51407-832-05, indicates a package size of 500 tablets, and includes barcodes. Dispensing instructions and storage conditions are provided. The labeler is GSMS, Incorporated, located in Camarillo, CA.*
FDA Label Image

51407-833-05lb (Lurasidone HCl)

51407-833-05lb (Lurasidone HCl)
Lurasidone Hydrochloride 80 mg film-coated tablets label showing prescription drug packaging by Golden State Medical Supply, Inc. The label includes NDC 51407-833-05, a green 80 mg strength marker, and indicates a 500 tablet count. It features storage instructions, dispensing guidelines, a barcode, and a QR code with sections for lot number and expiration date. Marked Rx only.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Lurasidone Hydrochloride, depicted as a molecular diagram showing its atomic connections and bonds.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A horizontal error bar plot titled Impact of other drugs on Lurasidone Pharmacokinetics (PK). It shows fold change and 90% confidence intervals in Cmax and AUC for Lurasidone when coadministered with various interacting drugs, including Ketoconazole, Diltiazem, Rifampin, and Lithium. The x-axis indicates change relative to Lurasidone alone from -4 to 4.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A dot plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters of various interacting drugs relative to their administration alone. Drugs listed include Digoxin 0.25 mg SD, Midazolam 5 mg SD, Ethinyl Estradiol, Norelgestromin, and Lithium 600 mg BID, with measured parameters such as Cmax, AUC, and Ctrough. The x-axis represents change relative to interactive drug alone, ranging from -1.0 to 1.0.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A pharmacokinetic chart depicting fold change and 90% confidence intervals for Lurasidone Hydrochloride concentration (Cmax) and exposure (AUC). It compares effects of renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population factors like gender (females) and race (Asian) relative to reference values. The x-axis shows change relative to reference from 0 to 6.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.